knowledge -WSS

knowledge

author：comprehensive 2025-09-07 21:57:32 - browse：7625

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Why Eli Lilly’s earnings didn’t quite live up to the hype

hotspot

WSS

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Congress considering partial increase for doctor pay in Medicare

What nurses really want: sufficient staffing for patient care

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Here’s what’s in the FDA plan to include pregnant women in clinical trials

hotspot

knowledge

focus

New air purifier tech could be key to improving indoor air quality

Congress might make insulin pumps more accessible to the blind

In age of alternative facts, a scholarly course on calling out crap

Brain worms: The science behind RFK Jr.'s parasitic infection

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

H5N1 communication has been strictly for the birds

Medicare proposal to cover medical devices draws a mixed reaction

Elevance, private equity launch primary care company

Medicare proposal to cover medical devices draws a mixed reaction

Bernie Sanders gets little from pharma CEOs on drug prices

Wikipedia

Why Eli Lilly’s earnings didn’t quite live up to the hype

Bird flu outbreak in cows is latest avian flu curveball

Elevance, private equity launch primary care company

Report cites 'urgent' need to recruit more diverse clinical trial participants

Elevance, private equity launch primary care company

Artificial intelligence use in health care faces greater scrutiny in 2024

focus

hotspot

leisure time

knowledge